Has the U.S. Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 39.6x which is lower than its 3-year average PE of 54.2x. The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 6.1x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 01 Jul 2026	US$2.6t	US$425.2b	US$65.7b	15.1x	39.6x	6.1x
Fri, 29 May 2026	US$2.4t	US$424.1b	US$66.3b	15.2x	35.8x	5.6x
Sun, 26 Apr 2026	US$2.2t	US$408.1b	US$66.8b	15.9x	32.6x	5.3x
Tue, 24 Mar 2026	US$2.2t	US$406.1b	US$72.0b	16.5x	30.6x	5.4x
Thu, 19 Feb 2026	US$2.4t	US$411.5b	US$73.9b	20.1x	32.3x	5.8x
Sat, 17 Jan 2026	US$2.3t	US$402.6b	US$71.5b	20.7x	31.8x	5.7x
Mon, 15 Dec 2025	US$2.2t	US$402.7b	US$71.4b	19.7x	30.8x	5.5x
Wed, 12 Nov 2025	US$2.0t	US$402.7b	US$71.3b	18.1x	28.2x	5x
Fri, 10 Oct 2025	US$1.9t	US$387.6b	US$61.0b	18.8x	31.3x	4.9x
Sun, 07 Sep 2025	US$1.8t	US$387.9b	US$61.0b	19x	29.2x	4.6x
Tue, 05 Aug 2025	US$1.7t	US$382.0b	US$54.8b	18.2x	31.5x	4.5x
Thu, 03 Jul 2025	US$1.7t	US$382.7b	US$61.3b	18.3x	28.4x	4.5x
Sat, 31 May 2025	US$1.7t	US$382.7b	US$61.2b	17.8x	27.2x	4.4x
Mon, 28 Apr 2025	US$1.8t	US$379.6b	US$63.1b	16.2x	28.5x	4.7x
Wed, 26 Mar 2025	US$1.9t	US$381.1b	US$41.3b	17x	46.1x	5x
Fri, 21 Feb 2025	US$1.9t	US$381.0b	US$39.0b	18.3x	47.8x	4.9x
Sun, 19 Jan 2025	US$1.8t	US$369.3b	US$31.2b	18.9x	56.1x	4.7x
Tue, 17 Dec 2024	US$1.8t	US$373.8b	US$30.7b	18.9x	59.3x	4.9x
Thu, 14 Nov 2024	US$1.9t	US$373.8b	US$30.7b	20.5x	61x	5x
Sat, 12 Oct 2024	US$2.0t	US$364.2b	US$25.3b	18.7x	79.2x	5.5x
Mon, 09 Sep 2024	US$2.0t	US$364.1b	US$25.5b	17.8x	79x	5.5x
Wed, 07 Aug 2024	US$1.9t	US$358.7b	US$21.7b	15.5x	85.8x	5.2x
Fri, 05 Jul 2024	US$1.9t	US$357.6b	US$13.8b	15x	140.4x	5.4x
Sun, 02 Jun 2024	US$1.9t	US$358.3b	US$14.1b	15.9x	133.4x	5.2x
Tue, 30 Apr 2024	US$1.8t	US$359.6b	US$17.5b	23x	102.8x	5x
Thu, 28 Mar 2024	US$1.9t	US$355.3b	US$22.6b	19.4x	84.3x	5.4x
Sat, 24 Feb 2024	US$1.9t	US$355.2b	US$24.0b	24.1x	80x	5.4x
Mon, 22 Jan 2024	US$1.8t	US$375.2b	US$33.9b	27.7x	51.8x	4.7x
Wed, 20 Dec 2023	US$1.7t	US$375.1b	US$33.9b	26.9x	49.4x	4.5x
Fri, 17 Nov 2023	US$1.6t	US$375.4b	US$33.7b	25.8x	48.5x	4.3x
Sun, 15 Oct 2023	US$1.7t	US$381.8b	US$43.8b	18.3x	38.9x	4.5x
Tue, 12 Sep 2023	US$1.8t	US$381.8b	US$43.9b	18x	40x	4.6x
Thu, 10 Aug 2023	US$1.8t	US$381.3b	US$44.5b	19x	40x	4.7x
Sat, 08 Jul 2023	US$1.7t	US$392.8b	US$60.2b	19x	27.7x	4.2x


US Market	1.92%
Healthcare	4.70%
Pharma	6.20%
Pharma	6.20%

Company	Last Price	7D	1Y	Valuation
LLY Eli Lilly	US$1.20k	8.3% +US$82.4b	54.6%	PE42.3x
JNJ Johnson & Johnson	US$253.97	6.2% +US$35.8b	62.9%	PE29.1x
MRK Merck	US$128.50	7.4% +US$22.0b	57.1%	PE35.5x
BMY Bristol-Myers Squibb	US$57.62	3.8% +US$4.3b	21.3%	PE16.2x
DFTX Definium Therapeutics	US$47.04	30.0% +US$2.3b	604.2%	PB22.4x

Announcement • Jun 30

Nuvation Bio Validates Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer in the United Kingdom

Nuvation Bio announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has validated the Marketing Authorisation Application (MAA) submitted by its partner Eisai Co, Ltd. for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The application was submitted through the International Recognition Procedure, which takes into account approvals from trusted regulatory partners and supports expedited access to medicines in the U.K. The application will now be evaluated by the MHRA to decide whether to approve or reject the application. In January 2026, Eisai and Nuvation Bio announced they had entered into an exclusive licensing and collaboration agreement in Europe and additional countries outside the U.S., China and Japan to extend the global reach of taletrectinib. Taletrectinib is an oral treatment for patients living with advanced ROS1+ NSCLC (marketed as IBTROZI® in the U.S. and Japan). In March 2026, the European Medicines Agency validated the MAA for taletrectinib. Additional filings are planned for Canada and other regions included in Eisai's licensed territories. Within the U.K., there are around 50,200 new lung cancer cases every year. Around 80 to 85% of all lung cancers are NSCLC, of which approximately 2% of patients harbor the ROS1+ mutation. The application is based on data from the two pivotal Phase 2 clinical studies, TRUST-I and TRUST-II, evaluating taletrectinib in patients globally. Results from a pooled analysis of the TRUST clinical program were originally published in the Journal of Clinical Oncology in April 2025, and updated data reflecting longer patient follow-up were presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, further building the efficacy and safety profile observed to date. Updated results from the TRUST-I study were also simultaneously published in April 2026 in the Journal of Clinical Oncology. In June 2025, the U.S. Food and Drug Administration (FDA) granted full approval to taletrectinib for the treatment of locally advanced or metastatic ROS1+ NSCLC across lines of therapy, following a Priority Review and double Breakthrough Therapy designations. Taletrectinib is also approved for patients with advanced ROS1+ NSCLC in Japan, where it is marketed by Nippon Kayaku, and in China, where it is marketed by Innovent Biologics under the brand name DOVBLERON®. Eisai's licensed territories: Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India. Each year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain. The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases. Taletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. The TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of taletrectinib. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating taletrectinib for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating taletrectinib for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating taletrectinib versus crizotinib in 194 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs. IRP is a regulatory pathway established by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) that allows the agency to take into account the expertise and decision-making of trusted international reference regulators, such as the European Medicines Agency (EMA) and FDA. Under IRP, MHRA conducts a targeted assessment based on existing regulatory evaluations, with the aim of supporting patients in the U.K. with expedited access to safe and effective medicines. IBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC). WARNINGS AND PRECAUTIONS: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients.

U.S. Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

US Lawmakers Open National Security Probe Into Merck Clinical Trials in China

Eli Lilly Surges Past Q1 Forecasts With Strong GLP-1 Demand and Raised 2026 Outlook

Teva Launches Ahzantive Biosimilar in Europe and Unveils Positive Austedo Clinical Data

Zoetis Hit by Securities Lawsuit Over Product Safety and Regulatory Disclosure Concerns

Pfizer Expands Cancer and Obesity Pipeline After $80 Billion in Recent Acquisitions

Nuvation Bio Validates Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer in the United Kingdom

Johnson & Johnson Buys Firefly Bio for $1 Billion and Unveils Cardiac Platform in Europe

Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell Microcap Growth Benchmark Index

Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 3000E Growth Benchmark

Independent Director notifies of intention to sell stock

Senior Vice President of Drug Discovery notifies of intention to sell stock

Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Growth-Defensive Index

Price target decreased by 18% to US$33.00

New major risk - Share price stability

TARS: Lyme Disease Prevention Trial Progress Will Drive Future Upside Potential

Veradermics Shows Strong Hair Growth Results and Raises US$767 Million for Lead Treatment